
Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford
– Successful completion of initial public offering with net proceeds of $126 million; cash and cash equivalents of $128 million as of September 30th- Additional $20 million in cash with an additional future option of $20 million through Oxford loan ame… […]